Diseases & Longevity · File 08

Sarcopenia. The frailty predictor nobody measures in time.

Sarcopenia — progressive loss of muscle mass, strength, and function associated with aging — affects 10 to 27% of adults 65 and older, and up to 50% in those over 80. It is an independent predictor of mortality, falls, hospitalization, and disability, and rarely appears in conventional consultation until clinical frailty is already established.

Why sarcopenia is an early-longevity disease

The loss of muscle mass starts, on average, around age 30 — at an estimated rate of 3-8% per decade that accelerates after 60. Strength loss is even faster than mass loss (dynapenia precedes structural sarcopenia). That is why sarcopenia is an early-longevity disease, not an old-age one.

The European consensus EWGSOP2 (Cruz-Jentoft et al., Age and Ageing 2019) redefined sarcopenia placing muscle strength as primary criterion (not mass). The three central clinical tests are: handgrip strength, gait speed, and chair-rise test. These measures are cheap, reproducible, and allow risk classification years before disability appears.

When strength is lost, reserve is lost. And muscle reserve is the most direct metric of functional aging we have.
EWGSOP2 · Cruz-Jentoft · 2019

The global weight, in numbers

Quantitative data on sarcopenia come from European cohorts (EWGSOP, SHARE), Latin American (ELSI-Brazil, SABE), and global meta-analyses. These are the points that guide the clinical conversation.

  • Prevalence in adults ≥65

    10–27%

    Global meta-analysis Yeung 2019 (JCSM): range varies by diagnostic criteria (EWGSOP, AWGS, FNIH) and region — but trend is consistent.
    — Yeung et al., J Cachexia Sarcopenia Muscle 2019

  • Estimated prevalence in ≥80

    50%

    Exponential acceleration after 80 — sarcopenia becomes the most frequent cause of autonomy loss in this age group.
    — Cruz-Jentoft et al., Age Ageing 2019

  • Increase in mortality risk

    2.5×

    Adults with confirmed sarcopenia have approximately 2.5× higher mortality risk at 5-10 years — independent of BMI, comorbidities, and functional level.
    — Liu et al., Maturitas 2017 meta-analysis

  • Increase in fall and fracture risk

    3×

    Sarcopenic adults have approximately 3× higher risk of falls and associated fracture — solid predictor that guides decision to intervene before clinical onset.
    — Yeung et al., JCSM 2019

Chap. 03 · Falls and fracture risk

Impact on quality of life and autonomy

Sarcopenia does not kill alone — but it disrupts the functional capacity that sustains independence. Consequences are quantified in disability, dependence, and healthcare cost.

  • Accelerated autonomy loss

    Beaudart PLOS ONE 2017

    Sarcopenia increases risk of dependence for basic (BADL) and instrumental (IADL) activities — one of the strongest predictors of institutionalization in older adults.

  • SF-36 PCS reduction

    Beaudart PLOS ONE 2017

    Adults with confirmed sarcopenia show consistent reductions in SF-36 physical component (PCS) — comparable to severe osteoarthritis or moderate COPD impact.

  • Hospitalization and prolonged stay

    Cruz-Jentoft Age Ageing 2019

    Sarcopenic adults have higher hospitalization frequency, longer hospital stay, and higher 30-day readmission rates — poor functional substrate amplifies any medical event.

  • Poor post-surgical recovery

    Joglekar JSO 2015

    Preoperative sarcopenia is an independent predictor of complications, 30-day mortality, prolonged stay, and poor functional recovery after major surgery (oncologic, orthopedic, cardiovascular).

Why a longevity protocol measures muscle, not just fat

The public health conversation has been centered on fat for decades — and that has produced a generation with normal BMI but low muscle mass and strength, what some authors call "hidden sarcopenic obesity." Muscle tissue is not only locomotor: it is an endocrine organ, glucose regulator, amino acid reservoir, and central component of older-adult immune function.

A longevity protocol does not replace the geriatrician or physiatrist when clinically indicated. What it does is what the conventional model rarely does in pre-frail patients: measures functional trajectory (handgrip, gait, body composition), evaluates anabolic resistance (hormonal profile, IGF-1, vitamin D, renal function), and integrates intervention (programmed strength training, high-biological-value protein, micronutrients, comorbidity optimization) under individual medical judgment — before deterioration becomes irreversible.

Muscle is the organ of functional longevity. Measuring it at 40 is measuring risk at 70.
How we measure it

How it is evaluated at Wellness Care

Three complementary layers under a longevity medicine protocol — none replaces specialized medical management when clinically indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications framing sarcopenia in the longevity conversation — European consensus, global meta-analysis, and quality-of-life data.

«La sarcopenia debe ser sospechada cuando hay pérdida de fuerza muscular — la masa muscular es el sustrato, pero la fuerza es el predictor funcional primario.»

Consenso EWGSOP2 — criterios diagnósticos
Cruz-Jentoft et al., Age Ageing 2019
Consenso EWGSOP2 — criterios diagnósticos

«La sarcopenia se asocia con un incremento aproximado de 3 veces en el riesgo de caídas y fracturas, y duplica o triplica el riesgo de hospitalización y mortalidad en adultos mayores.»

Meta-análisis global de prevalencia y consecuencias
Yeung et al., JCSM 2019
Meta-análisis global de prevalencia y consecuencias

«Los pacientes con sarcopenia confirmada muestran reducciones consistentes en SF-36 PCS, mayor frecuencia de dependencia y peor percepción de salud general — efecto independiente de comorbilidades.»

Calidad de vida en sarcopenia confirmada
Beaudart et al., PLOS ONE 2017
Calidad de vida en sarcopenia confirmada

Frequently asked questions about sarcopenia

The most recurrent questions about sarcopenia, EWGSOP2 diagnostic criteria, and why longevity medicine measures body composition and strength years before disability appears.

01

At what age should I start worrying about sarcopenia?

Muscle mass loss starts around 30, at 3-8% per decade. That is the age to start measuring, not the age to worry.

Typical trajectory:

· 50-65 — pre-sarcopenia (low mass without strength loss) in sedentary people
· ≥65 — established clinical sarcopenia frequent
· ≥80 — exceeds 40-50%

02

How is sarcopenia diagnosed in consultation?

EWGSOP2 criteria use a three-step algorithm:

1. Clinical suspicion — SARC-F questionnaire or gait speed drop
2. Confirmation — handgrip strength or chair-rise test
3. Quantification — appendicular muscle mass by DEXA or BIA

Severity: gait speed < 0.8 m/s indicates severe sarcopenia.

03

How much protein should an older adult consume to prevent sarcopenia?

PROT-AGE guidelines (Bauer 2013 JAMDA) recommend:

· 1.0-1.2 g/kg/day in healthy older adults
· 1.2-1.5 g/kg/day in presence of acute or chronic illness

Significantly above the classical 0.8 g/kg RDA.

Uniform distribution across meals (~25-30 g per meal) maximizes muscle protein synthesis. Leucine (3 g per meal) is the most anabolic amino acid.

04

Does resistance training really reverse sarcopenia?

Yes, partially and proportional to intensity.

Cochrane reviews and meta-analyses show that progressive resistance training (2-3 sessions per week, 6-12 months) produces significant gains in:

· Muscle mass
· Maximal strength
· Functional performance

Even in adults 80+.

High-biological-value protein combination potentiates the effect. Aerobic exercise alone is insufficient — it does not adequately stimulate hypertrophy or strength.

05

Which biomarkers evaluate anabolic resistance?

In longevity medicine we evaluate:

· Hormonal profile — total/free testosterone, DHEA-S, IGF-1, thyroid, cortisol
· Vitamin D (25-OH)
· Renal function — creatinine, cystatin C, eGFR
· Hepatic function
· Nutrition — albumin, prealbumin, transferrin
· Inflammaging — hsCRP, IL-6, TNF-α
· Quantitative body composition — DEXA with appendicular muscle mass, BIA

The pattern guides clinical decision.

06

When should I consult for suspected sarcopenia?

A functional assessment is worthwhile if:

· You notice strength loss (struggling to open jars, lift objects, climb stairs)
· You have lost visible muscle mass without intentional diet
· Your gait speed has decreased
· You have had recent falls
· You are 50+ and want to anticipate

The 5-item SARC-F questionnaire is a good starting point and can be applied in general consultation.

The organ of functional longevity

Muscle is not only locomotor — it is endocrine, metabolic, and immune. Losing it at 50 is compromising the trajectory at 80.

Measure body composition and strength, evaluate anabolic resistance, integrate strength training and protein under individual medical judgment — years before clinical disability appears. That is functional longevity.

Noticing strength or muscle loss?

Book a functional and body composition assessment

We evaluate body composition (DEXA or BIA), handgrip strength, gait speed, anabolic profile (hepatic, hormonal, IGF-1), and inflammaging biomarkers. If you've noticed strength loss, body composition changes, or are over 50 and want to anticipate — this is what we do.

Book sarcopenia assessment